New anti ed drugs are approved for clinical research

Recently, the reporter learned from the Shanghai Institute of pharmaceutical research of the Chinese Academy of Sciences that the tpn729 and its tablets, a new class 1.1 drug jointly researched and developed by the Shen Jingshan research group and Jiang Hualiang research group of the Institute, have obtained the "approval for clinical trials of drugs" issued by the state food and Drug Administration and have been approved to enter the phase I clinical trials The drug is expected to become the first innovative drug with independent intellectual property rights for male erectile dysfunction (ED) indications in China Tpn729 is a highly selective type 5 phosphodiesterase (PDE5) inhibitor, which can be used in the treatment of erectile dysfunction (ED) and pulmonary hypertension (PAH) "The use mechanism of Viagra is basically the same." The new drug tpn729 has the characteristics of high activity, good selectivity, clear efficacy, low toxicity and excellent pharmacokinetic properties, Shen said Especially in activity, the activity of tpn729 is several times that of Viagra, which means that only a fraction of the original dose of Viagra can achieve the effect At the same time, it can also reduce some adverse reactions of PDE5 inhibitors According to reports, the development process of new drug tpn729 is more than ten years The researchers tested and screened more than 1000 compounds, seven of which were screened in each round, and conducted a large number of experiments on experimental mice and dogs Shen Jingshan said that entering phase I clinical trial does not mean tpn729 can be officially launched in a short time If the trial is successful, it will take another two to three years It is understood that the pre clinical research work of tpn729 also includes the drug safety evaluation research center of Shanghai Pharmaceutical Research Institute, Shanghai drug metabolism research center and the school of pharmacy of Zhejiang University.